Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: URT035
MIFTS: 31

Urethral Benign Neoplasm

Categories: Cancer diseases
Genes Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Urethral Benign Neoplasm

About this section

MalaCards integrated aliases for Urethral Benign Neoplasm:

Name: Urethral Benign Neoplasm 12 15
Urethral Neoplasms 45 74
Malignant Neoplasm of Urethra 74
Neoplasm of Urethra 12
Urethral Carcinoma 74
Neoplasm. Urethra 12
Urethral Neoplasm 17

Classifications:

MalaCards categories:
Global: Cancer diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:730
MeSH 45 D014523
NCIt 51 C3428
ICD10 34 C68.0
Sources

Summaries for Urethral Benign Neoplasm

About this section
MalaCards based summary : Urethral Benign Neoplasm, also known as urethral neoplasms, is related to urethra leiomyoma and urethra cancer. An important gene associated with Urethral Benign Neoplasm is KRT20 (Keratin 20). The drugs Cisplatin and Gemcitabine have been mentioned in the context of this disorder. Affiliated tissues include kidney, appendix and colon.

Sources

Related Diseases for Urethral Benign Neoplasm

About this section

Diseases related to Urethral Benign Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 134)
# Related Disease Score Top Affiliating Genes
1 urethra leiomyoma 11.3
2 urethra cancer 10.2
3 fibroepithelial basal cell carcinoma 10.1 CEACAM5 KRT20
4 rete testis adenocarcinoma 10.1 CEACAM5 KRT20
5 rete testis neoplasm 10.1 CEACAM5 KRT20
6 cystadenocarcinoma 10.0 CEACAM5 KRT7
7 cutaneous mucoepidermoid carcinoma 10.0 CEACAM5 KRT7
8 mucoepidermoid carcinoma 10.0 CEACAM5 KRT7
9 anal gland adenocarcinoma 10.0 CEACAM5 KRT7
10 mucinous adenofibroma 10.0 CEACAM5 KRT7
11 anus adenocarcinoma 10.0 CEACAM5 KRT7
12 malignant spiradenoma 10.0 CEACAM5 KRT7
13 bile duct mucoepidermoid carcinoma 10.0 CEACAM5 KRT7
14 cutaneous adenocystic carcinoma 10.0 CEACAM5 KRT7
15 nodular hidradenoma 10.0 CEACAM5 KRT7
16 adenoid basal cell carcinoma 10.0 CEACAM5 KRT7
17 pancreatic serous cystadenoma 10.0 CEACAM5 KRT7
18 eccrine adenocarcinoma 10.0 CEACAM5 KRT7
19 malignant biphasic mesothelioma 10.0 CEACAM5 KRT7
20 prostate squamous cell carcinoma 9.9 CEACAM5 KRT7
21 mucinous ovarian cystadenoma 9.9 CEACAM5 KRT7
22 warthin tumor 9.9 CEACAM5 KRT7
23 breast adenomyoepithelioma 9.9 CEACAM5 KRT7
24 breast myoepithelial neoplasm 9.9 CEACAM5 KRT7
25 papilloma 9.9 KRT20 KRT7
26 basal cell carcinoma 9.9 KRT20 KRT7
27 cystadenoma 9.9 KRT20 KRT7
28 cystic basal cell carcinoma 9.9 KRT20 KRT7
29 seminal vesicle adenocarcinoma 9.9 KRT20 KRT7
30 transverse colon cancer 9.9 KRT20 KRT7
31 appendix adenocarcinoma 9.9 KRT20 KRT7
32 malignant syringoma 9.9 KRT20 KRT7
33 mixed cell type cancer 9.9 CEACAM5 KRT7
34 glandular cystitis 9.9 KRT20 KRT7
35 papillary transitional carcinoma 9.9 KRT20 KRT7
36 eyelid carcinoma 9.9 KRT20 KRT7
37 krukenberg carcinoma 9.9 KRT20 KRT7
38 large intestine adenocarcinoma 9.9 KRT20 KRT7
39 linitis plastica 9.9 KRT20 KRT7
40 lung acinar adenocarcinoma 9.9 KRT20 KRT7
41 small cell carcinoma of the bladder 9.9 KRT20 KRT7
42 small cell carcinoma 9.9 KRT20 KRT7
43 adenoid squamous cell carcinoma 9.9 KRT20 KRT7
44 intratubular embryonal carcinoma 9.9 KRT20 KRT7
45 bile duct adenoma 9.9 KRT20 KRT7
46 jejunal adenocarcinoma 9.9 KRT20 KRT7
47 ovarian mucinous adenocarcinoma 9.9 KRT20 KRT7
48 mucinous adenocarcinoma 9.9 KRT20 KRT7
49 appendix disease 9.9 KRT20 KRT7
50 gastric diffuse adenocarcinoma 9.9 KRT20 KRT7

Comorbidity relations with Urethral Benign Neoplasm via Phenotypic Disease Network (PDN):


Acute Cystitis Bladder Cancer
Hydronephrosis Prostate Cancer
Prostatic Hypertrophy

Graphical network of the top 20 diseases related to Urethral Benign Neoplasm:



Diseases related to Urethral Benign Neoplasm
Sources

Symptoms & Phenotypes for Urethral Benign Neoplasm

About this section
Sources

Drugs & Therapeutics for Urethral Benign Neoplasm

About this section

Drugs for Urethral Benign Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 98)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
2
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
3
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
4
leucovorin Approved Phase 3,Phase 2 58-05-9 143 6006
5
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
6
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
7
Vinblastine Approved Phase 3,Phase 2,Phase 1 865-21-4 241903 13342
8
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
9
Bevacizumab Approved, Investigational Phase 3 216974-75-3
10
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
11
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
12 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
13 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
14 Immunologic Factors Phase 3,Phase 2,Phase 1
15 Antimetabolites Phase 3,Phase 2,Phase 1
16 Anti-Infective Agents Phase 3,Phase 2,Phase 1
17 Antiviral Agents Phase 3,Phase 2,Phase 1
18 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
19 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
20 Folate Phase 3,Phase 2
21 Antimitotic Agents Phase 3,Phase 2,Phase 1
22 Antirheumatic Agents Phase 3,Phase 2
23 Dermatologic Agents Phase 3,Phase 2,Phase 1
24 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
25 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
26 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
27 Vitamin B Complex Phase 3,Phase 2
28 Anti-Bacterial Agents Phase 3,Phase 1,Phase 2
29 Folic Acid Antagonists Phase 3,Phase 2
30 Vitamin B9 Phase 3,Phase 2
31 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
32 Antibiotics, Antitubercular Phase 3,Phase 1,Phase 2
33 Antineoplastic Agents, Immunological Phase 3,Phase 2,Phase 1
34 Immunoglobulins Phase 3,Phase 2,Phase 1
35 Immunoglobulin G Phase 3,Phase 1
36 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
37 Antibodies Phase 3,Phase 2,Phase 1
38 Endothelial Growth Factors Phase 3
39 Mitogens Phase 3
40
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
41
Fluorouracil Approved Phase 2 51-21-8 3385
42
Ifosfamide Approved Phase 2 3778-73-2 3690
43
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
44
Everolimus Approved Phase 1, Phase 2 159351-69-6 70789204 6442177
45
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
46
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 46835353 5284616 6436030
47
Lenograstim Approved, Investigational Phase 2 135968-09-1
48
Docetaxel Approved, Investigational Phase 2,Phase 1 114977-28-5 148124
49
Arsenic trioxide Approved, Investigational Phase 2 1327-53-3 518740
50
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 60843 446556

Interventional clinical trials:

(show top 50) (show all 69)
# Name Status NCT ID Phase Drugs
1 Combination Chemotherapy in Treating Patients With Bladder Cancer Completed NCT00003701 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride;methotrexate;paclitaxel;vinblastine sulfate
2 Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium Completed NCT00003376 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride;methotrexate;paclitaxel;vinblastine
3 Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer Completed NCT00022191 Phase 3 cisplatin;gemcitabine hydrochloride;paclitaxel
4 Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium Completed NCT00014274 Phase 2, Phase 3 carboplatin;gemcitabine hydrochloride;methotrexate;vinblastine sulfate
5 Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma Recruiting NCT03296306 Phase 3 Treatment duration of cisplatin based chemotherapy
6 Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Active, not recruiting NCT00942331 Phase 3 Cisplatin;Gemcitabine Hydrochloride
7 Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer Unknown status NCT01118039 Phase 2 sunitinib malate
8 Surgery Plus Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Urinary Tract Unknown status NCT00006111 Phase 2 cisplatin;fluorouracil
9 A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer Unknown status NCT01326871 Phase 1, Phase 2 Cisplatin;Gemcitabine
10 TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium Completed NCT00077688 Phase 2 TOCOSOL Paclitaxel
11 S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium Completed NCT00055835 Phase 2 carboplatin;cisplatin;gemcitabine hydrochloride;paclitaxel
12 Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer Completed NCT00002684 Phase 2 cisplatin;ifosfamide;paclitaxel
13 Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer Completed NCT01191892 Phase 2 carboplatin;gemcitabine hydrochloride;vandetanib;Placebo
14 Pazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relapsed or Not Responded to Treatment Completed NCT01031875 Phase 2 pazopanib hydrochloride
15 Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium Completed NCT01090466 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride;temsirolimus
16 Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract Completed NCT00002914 Phase 2 piritrexim
17 Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium Completed NCT00080795 Phase 2 cisplatin;doxorubicin hydrochloride;gemcitabine hydrochloride;ifosfamide
18 Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract Completed NCT00006026 Phase 2 rubitecan
19 Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer Completed NCT00004223 Phase 2 docetaxel;gemcitabine hydrochloride
20 Arsenic Trioxide in Treating Patients With Urothelial Cancer Completed NCT00009867 Phase 2 arsenic trioxide
21 Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium Completed NCT00053209 Phase 2 gemcitabine hydrochloride;pemetrexed disodium
22 S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium Completed NCT00045630 Phase 2 carboplatin;gemcitabine;paclitaxel
23 SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract Completed NCT00006351 Phase 2 gemcitabine hydrochloride;lonafarnib
24 Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function Completed NCT00005644 Phase 2 gemcitabine hydrochloride;paclitaxel
25 Pazopanib in Treating Patients With Metastatic Urothelial Cancer Completed NCT00471536 Phase 2 pazopanib hydrochloride
26 Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium Completed NCT00397488 Phase 2 sunitinib malate
27 Fluorouracil in Treating Patients With Recurrent or Metastatic Bladder Cancer Completed NCT00003175 Phase 2 fluorouracil
28 S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract Completed NCT00014144 Phase 2 gefitinib
29 S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy Completed NCT00066612 Phase 2 irinotecan hydrochloride
30 A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer Completed NCT00661609 Phase 2 AZD4877
31 Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT) Completed NCT01089088 Phase 2 cisplatin;gemcitabine hydrochloride;sunitinib malate
32 Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function Completed NCT00478361 Phase 2 Gemcitabine hydrochloride;Paclitaxel;Doxorubicin hydrochloride;Pegfilgrastim
33 Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma Completed NCT00072150 Phase 2 bortezomib
34 Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer Completed NCT00021099 Phase 2 ixabepilone
35 VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium Completed NCT00407485 Phase 2
36 LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer Recruiting NCT02612194 Phase 2 Crizotinib
37 A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer Recruiting NCT03219333 Phase 2 Enfortumab vedotin
38 Afatinib in Advanced Refractory Urothelial Cancer Recruiting NCT02122172 Phase 2 afatinib dimaleate
39 Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer Recruiting NCT03237780 Phase 2 Atezolizumab;Eribulin Mesylate
40 Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma Recruiting NCT03513952 Phase 2 Atezolizumab
41 Cabozantinib for Advanced Urothelial Cancer Active, not recruiting NCT01688999 Phase 2 Cabozantinib
42 Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant Active, not recruiting NCT00082706 Phase 2 5-Fluorouracil (5-FU);Leucovorin;Cisplatin;Gemcitabine
43 Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery Active, not recruiting NCT02178241 Phase 2 Eribulin Mesylate;Gemcitabine Hydrochloride
44 Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer Active, not recruiting NCT03617913 Phase 2 Avelumab;Cisplatin;Fluorouracil;Mitomycin
45 A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function Active, not recruiting NCT02665039 Phase 2 Vinflunine;Gemcitabine;Carboplatin
46 Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer Active, not recruiting NCT00749892 Phase 2 Erlotinib Hydrochloride
47 Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer Terminated NCT01611662 Phase 2 gemcitabine hydrochloride;cisplatin
48 S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract Terminated NCT00022633 Phase 2 gemcitabine hydrochloride;paclitaxel
49 S0400, FR901228 in Treating Patients With Advanced Cancer of the Urothelium Terminated NCT00087295 Phase 2 Depsipeptide
50 Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium Terminated NCT00004856 Phase 2

Search NIH Clinical Center for Urethral Benign Neoplasm

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: urethral neoplasms

Sources

Genetic Tests for Urethral Benign Neoplasm

About this section
Sources

Anatomical Context for Urethral Benign Neoplasm

About this section

MalaCards organs/tissues related to Urethral Benign Neoplasm:

42
Kidney, Appendix, Colon, Ovary, Endothelial, Testis, Thymus
Sources

Publications for Urethral Benign Neoplasm

About this section

Articles related to Urethral Benign Neoplasm:

# Title Authors Year
1
Primary urethral neoplasms: review of 30 cases. ( 6259375 )
1981
Sources

Variations for Urethral Benign Neoplasm

About this section
Sources

Expression for Urethral Benign Neoplasm

About this section
Search GEO for disease gene expression data for Urethral Benign Neoplasm.
Sources

Pathways for Urethral Benign Neoplasm

About this section
Sources

GO Terms for Urethral Benign Neoplasm

About this section

Cellular components related to Urethral Benign Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intermediate filament GO:0005882 8.62 KRT20 KRT7

Biological processes related to Urethral Benign Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 keratinization GO:0031424 8.96 KRT20 KRT7
2 cornification GO:0070268 8.62 KRT20 KRT7
Sources

Sources for Urethral Benign Neoplasm

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....